Home › NDC Lookup › RxCUI directory › RxCUI 2627781

Metaxalone 640 MG Oral Tablet — RxCUI 2627781

RxNorm drug concept · Semantic clinical drug
RxCUI 2627781 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2627781
Official nameMetaxalone 640 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)1,716 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Metaxalone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It helps relieve discomfort from sudden, painful muscle and bone conditions. It is meant to be used along with rest and physical therapy, not by itself. It is for adults and teens...
  • Take it by mouth, with or without food, usually three to four times a day as your prescriber directs. Don't take more than prescribed. If you were on Skelaxin 800 mg, don't switch...
  • The most common are drowsiness, dizziness, headache, feeling nervous or irritable, nausea, vomiting and stomach upset. Be careful driving until you know how it affects you.
  • It's best to avoid it. Alcohol and other sedating medicines can add to the sleepiness and may slow your breathing.
📖 Read our full Metaxalone guide →

🕸️ Concept Web — How Metaxalone 640 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Metaxalone 640 MG Oral Tablet RxCUI 2627781

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Metaxalone 59078
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Metaxalone Oral Tablet 372801
    • Metaxalone Oral Product 1156711
    • Metaxalone Pill 1156712
    • Oral Tablet 317541
    • Oral Product 1151131
    • Pill 1151133
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Metaxalone 640 MG 2627780

Showing up to 8 concepts per family — 8 of 8 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Metaxalone 640 MG SCDC · 2627780
  • Metaxalone Oral Tablet SCDF · 372801
  • Metaxalone Oral Product SCDG · 1156711
  • Metaxalone Pill SCDG · 1156712

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2627781 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
74157-0018-60 60 TABLET in 1 BOTTLE (74157-018-60) Metaxalone INA Pharmaceutics Inc 2025-02-10
Observed labelers: INA Pharmaceutics Inc (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.